Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and binding affinity for BCR-ABL compared with imatinib. Nilotinib is approved in patients with imatinib-resistant and -intolerant Philadelphia chromosome-positive chronic myeloid leukemia (CML), as well as in patients with newly diagnosed CML. Nilotinib is generally well tolerated, with mild and manageable side effects, and is associated with some adverse events that require management to insure patient adherence to therapy and optimal treatment outcomes. The objectives of this article are to review the clinical management of the most frequent of these adverse events and to guide physicians in helping their patients maintain adherence and achieve optimal outcomes with nilotinib therapy.

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML / Gianantonio Rosti;Fausto Castagnetti;Gabriele Gugliotta;Francesca Palandri;Michele Baccarani. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - STAMPA. - 38:(2012), pp. 241-248. [10.1016/j.ctrv.2011.07.004]

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

ROSTI, GIANANTONIO;CASTAGNETTI, FAUSTO;GUGLIOTTA, GABRIELE;PALANDRI, FRANCESCA;BACCARANI, MICHELE
2012

Abstract

Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and binding affinity for BCR-ABL compared with imatinib. Nilotinib is approved in patients with imatinib-resistant and -intolerant Philadelphia chromosome-positive chronic myeloid leukemia (CML), as well as in patients with newly diagnosed CML. Nilotinib is generally well tolerated, with mild and manageable side effects, and is associated with some adverse events that require management to insure patient adherence to therapy and optimal treatment outcomes. The objectives of this article are to review the clinical management of the most frequent of these adverse events and to guide physicians in helping their patients maintain adherence and achieve optimal outcomes with nilotinib therapy.
2012
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML / Gianantonio Rosti;Fausto Castagnetti;Gabriele Gugliotta;Francesca Palandri;Michele Baccarani. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - STAMPA. - 38:(2012), pp. 241-248. [10.1016/j.ctrv.2011.07.004]
Gianantonio Rosti;Fausto Castagnetti;Gabriele Gugliotta;Francesca Palandri;Michele Baccarani
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/397922
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 21
social impact